Healthcare

● Azitra is built on engineering Staphylococcus epidermidis, a bacterium naturally found on human skin, to produce useful proteins where needed.

Trust Stamp Inc reported a significant 22% increase in revenue for the first half of 2026, reflecting strong demand for its identity verification services primarily driven by engagements with clients in the telecommunications sector. The company generated $1.66 million in net recognized revenue, rising …

Dogwood Therapeutics, Inc. (NASDAQ: DWTX), a development-stage biopharmaceutical company focused on non-opioid pain treatments, announced a net loss of $11.5 million for the second quarter ending June 30, 2026. This loss translates to $0.34 per share, significantly higher than the $3.8 million loss reported …

Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a major player in the pharmaceuticals industry with a marketCapitalizationof approximately $44 million, reported total revenue of $33.4 million for the second quarter of 2026. Investor concerns are mounting as the company grapples with decreases in both total and …

MeiraGTx Holdings plc (NASDAQ: MGTX) has achieved a remarkable turnaround with a net income of $160.7 million for the quarter ending June 30, 2026. This stark contrast comes after reporting a net loss of $38.8 million for the same quarter in 2025. The substantial …

Parabilis Medicines, Inc. (NASDAQ: PBLS), a clinical-stage biopharmaceutical company, reported a strong cash position of $1.1 billion as of June 30, following a successful upsized initial public offering (IPO) that raised $770.5 million. The substantialCapitalincreases the company's financial flexibility to fund its ongoing research …

Pulmatrix, Inc. (NASDAQ: PULM) is a micro‑cap biopharmaceutical firm with aMarket Capitalisationof $6 million, 3,652,285 shares outstanding and $2.2 million in cash and cash equivalents. The company focuses on inhaled therapeutics built on its iSPERSE™ platform and is managing a strategic consolidation with Eos …